dosulepin hydrochloride

CLINICAL USE

Tricyclic antidepressant

DOSE IN NORMAL RENAL FUNCTION

50–225 mg daily

PHARMACOKINETICS

  • Molecular weight                           :331.9
  • %Protein binding                           :84
  • %Excreted unchanged in urine     : 56 (mainly as metabolites)
  • Volume of distribution (L/kg)       :45
  • half-life – normal/ESRD (hrs)      :14–24/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Start with small dose, and titrate according to response
  • <10           : Start with small dose, and titrate according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in GFR <10 mL/min
  • HD                     :Not dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Alcohol: increased sedative effect
  • Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid concomitant use; increased risk of ventricular arrhythmias with drugs that prolong the QT interval; increased risk of arrhythmias with propafenone
  • Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin – avoid concomitant use; concentration reduced by rifampicin
  • Anticoagulants: may alter anticoagulant effect of coumarins
  • Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide – avoid concomitant use; concentration possibly increased with SSRIs
  • Anti-epileptics: convulsive threshold lowered; concentration reduced by carbamazepine, primidone, barbiturates and possibly phenytoin
  • Antimalarials: avoid concomitant use with artemether/lumefantrine
  • Antipsychotics: increased risk of ventricular arrhythmias especially with pimozide; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics
  • Antivirals: increased tricyclic side effects with amprenavir; concentration possibly increased with ritonavir
  • Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions
  • Beta-blockers: increased risk of ventricular arrhythmias with sotalol
  • Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal
  • Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline
  • Pentamidine: increased risk of ventricular arrhythmias
  • Sibutramine: increased risk of CNS toxicity – avoid concomitant use.
  • Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    –dosulepin hydrochloride (dothiepin).DOSULePIN HYDROCHLORIDe (DOtHIePIN) 251

    OTHER INFORMATION

    Metabolites are active and partly renally excretedMetabolites accumulate and cause excessive sedation25–50 mg usually effective without too much sedation.

  • Related News